耐多药肺结核手术治疗的评价

发布时间：2018-05-06 02:28

本文选题：耐多药肺结核 + 手术治疗　；参考：《重庆医科大学》2013年硕士论文

【摘要】：结核分枝杆菌（Mycobacterium tuberculosis，MTB）耐多药的产生严重加大了肺结核治疗的难度，，使患者的生活质量严重下降，死亡率大大增加，是全球结核病疫情控制的巨大阻碍，对耐多药肺结核治疗方法的改进提出了新的挑战[1-3]。由于内科有效化疗药物开发进度缓慢，耐多药肺结核病患者对手术治疗的需求将逐渐增加。耐多药肺结核若已经发展至严重肺部毁损，导致慢性呼吸衰竭，患者将不能耐受手术治疗，手术者也将无法进行手术，这部分患者基本上是在等待死亡。本综述主要探讨耐多药患者手术治疗的重要性，手术时机的把握及手术适应证选择的重要性。旨在对耐多药肺结核患者延迟手术治疗，错失手术时机，这一现象提出警示。
[Abstract]:The production of multi-drug resistance of Mycobacterium tuberculosism MTB has seriously increased the difficulty of tuberculosis treatment, seriously reduced the quality of life of patients and greatly increased the mortality rate, which is a huge obstacle to the control of the global tuberculosis epidemic situation. A new challenge to improve the treatment of multi-drug resistant pulmonary tuberculosis [1-3]. Due to the slow development of effective chemotherapeutic drugs in internal medicine, the demand for surgical treatment of MDR-TB patients will increase gradually. If MDR-TB has developed to severe lung damage, resulting in chronic respiratory failure, patients will not be able to tolerate surgical treatment, surgery will also be unable to perform surgery, this part of the patient is basically waiting to die. This review focuses on the importance of surgical treatment, timing of operation and selection of surgical indications for multidrug resistant patients. The aim of this paper is to warn patients with multi-drug-resistant pulmonary tuberculosis (MDR) of delayed surgical treatment and missed surgical opportunity.
【学位授予单位】：重庆医科大学
【学位级别】：硕士
【学位授予年份】：2013
【分类号】：R655.3

【参考文献】